{
  "docId": "019de073-a59c-77cf-8e75-229e6c5c9530",
  "docSlug": "74412512a1adb89488775a4a2b6a1b7b",
  "documentTitle": "Avenue Therapeutics | IPO Presentation Deck | 30 slides",
  "authorId": "avenue-therapeutics",
  "authorName": "Avenue Therapeutics",
  "documentKindSlug": "regulatory-filing",
  "documentKindLabel": "Regulatory filing",
  "sourceTypeSlug": "investment_bank",
  "sourceTypeLabel": "Investment bank",
  "presentationDate": "2022-10-01 00:00:00",
  "orientation": "landscape",
  "aspectRatio": 1.7761332,
  "pageNumber": 30,
  "pageCount": 30,
  "prevPage": 29,
  "nextPage": null,
  "slideType": "executive_summary",
  "function": "summarize",
  "density": "dense",
  "nDataPoints": 0,
  "notes": null,
  "elementsJson": null,
  "metadataConfidence": 1,
  "imagePath": null,
  "slideHref": "/slides/019de073-a59c-77cf-8e75-229e6c5c9530/30",
  "deckHref": "/decks/019de073-a59c-77cf-8e75-229e6c5c9530",
  "deckJsonHref": "/decks/019de073-a59c-77cf-8e75-229e6c5c9530.json",
  "deckAnchorHref": "/decks/019de073-a59c-77cf-8e75-229e6c5c9530#slide-30",
  "components": [
    {
      "bbox": {
        "h": 1,
        "w": 0.38,
        "x": 0.62,
        "y": 0
      },
      "kind": "image",
      "text": null,
      "attrs": null,
      "subkind": "illustration",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "2b88932d-af30-4fb8-89fa-4ad0df884dd5",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.6,
        "w": 0.55,
        "x": 0.04,
        "y": 0.2
      },
      "kind": "list",
      "text": "Avenue Therapeutics is a specialty pharmaceutical company that seeks to develop and commercialize therapies to treat central nervous system (CNS) conditions. Our portfolio will soon include two clinical stage programs that we believe each have a significant market potential: IV Tramadol (Phase 3) for acute postoperative surgical pain and BAER-101* (Phase 1b) for epilepsy and acute anxiety. Our clinical development programs are designed to meet near-term milestones that could build near-term value. Potential to continue to expand pipeline through additional acquisitions in the rare / CNS disease space.",
      "attrs": null,
      "subkind": "bullet",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "086f14ef-ca98-486e-bba9-71e4c46401ba",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.05,
        "w": 0.35,
        "x": 0.18,
        "y": 0.93
      },
      "kind": "source-note",
      "text": "* Pending close of Share Contribution Agreement with Fortress Biotech, Inc. for Baergic Bio, Inc.",
      "attrs": null,
      "subkind": null,
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "4625812e-1dc5-4e2a-8166-2c86cfcae3f4",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.05,
        "w": 0.25,
        "x": 0.04,
        "y": 0.11
      },
      "kind": "title",
      "text": "Executive Summary",
      "attrs": null,
      "subkind": "headline",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "5808029f-e5db-4147-a146-5985904c5c12",
      "frameworkName": null,
      "frameworkSlug": null
    }
  ],
  "metrics": [],
  "tools": [],
  "frameworks": [],
  "arcBeats": [],
  "loops": [],
  "imagePathAlt": null,
  "thumbSrc": null,
  "thumbSrcAlt": null,
  "locked": true
}